Navicixizumab

Names

[ Name ]:
Navicixizumab

Biological Activity

[Description]:

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Stem Cell/Wnt >> Notch

[Target]

IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM)

[In Vitro]

Navicixizumab (0-100 μM) 在 hVEGF 存在的情况下减少人内皮细胞的增殖[3].

[In Vivo]

Navicixizumab (15 mg/kg，每周一次，持续 4 周) 抑制结肠异种移植肿瘤的生长[3]。

[References]

[1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577.

[2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705.

[3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.

Chemical & Physical Properties

No Any Chemical & Physical Properties